Shanghai Haoyuan Chemexpress Co., Ltd.

Shanghai Stock Exchange 688131.SS

Shanghai Haoyuan Chemexpress Co., Ltd. Price to Sales Ratio (P/S) on January 27, 2025: 4.20

Shanghai Haoyuan Chemexpress Co., Ltd. Price to Sales Ratio (P/S) is 4.20 on January 27, 2025, a 39.93% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Shanghai Haoyuan Chemexpress Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 5.14 on November 11, 2024, which is 22.29% above the current Price to Sales Ratio (P/S).
Shanghai Haoyuan Chemexpress Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 1.43 on July 04, 2024, which is -66.07% below the current Price to Sales Ratio (P/S).
Shanghai Haoyuan Chemexpress Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 2.95.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shanghai Stock Exchange: 688131.SS

Shanghai Haoyuan Chemexpress Co., Ltd.

CEO	Mr. Baofu Zheng
IPO Date	June 8, 2021
Location	China
Headquarters	No. 3 Building, No. 1999
Employees	3,370
Sector	Health Care
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials

Description

Shanghai Haoyuan Chemexpress Co., Ltd. researches and develops pharmaceutical intermediates and small molecule drugs. It manufactures APIs and API intermediates, vitamin D series compounds, CRO building blocks, and CRO life bioscience compounds. The company was founded in 2006 and is headquartered in Shanghai, China.

Key trends

Past 5 years